


Probiotic Yeast

A Unique Asset for Gut Health



Mycobiota: the yeast component of the microbiota



► **Mycobiota** is the community of beneficial fungi and yeast within the gut microbiota. It represents about **0.1%** of the microbial communities in the digestive tract ⁽¹⁾

► **S. cerevisiae** is among the most abundant fungi in the GI tract with beneficial effects

What Makes Probiotic Yeasts Different?

Probiotic yeasts improve digestive health by protecting the normal microbiota of the human gut and enhancing immune function through stimulation of the body's natural defenses⁽²⁾. But what makes probiotic yeasts fundamentally different from bacterial probiotics?

Cellular Nature⁽³⁾
Yeasts (eukaryotic) are 10 times larger than a bacterial cell (Prokaryotic) which enhances their **ability to bind to pathogens** and facilitate their elimination from the gut.

Survival rate⁽⁴⁾
Yeast cells **naturally survive gastric passage** (stomach acid) whereas many bacterial probiotics require encapsulation or protection technologies.

No colonization effect⁽⁵⁾
Yeasts enhance gut diversity **without settling permanently**, supporting an adaptable microbial ecosystem and preserving natural microbiota balance. Though transient, they exert beneficial effects throughout their passage.

Superior Stability
Yeast is more resistant to heat, oxygen, and has a **longer shelf-life** (often no strict refrigeration needed).

Antibiotic-Resistance: A Unique Property of Yeasts

Anytime antibiotics are used, they can cause side effects. The antibiotics not only destroy pathogenic bacteria, but also useful bacteria and **can cause a dysbiosis** of the microbiome in the gastrointestinal tract. ⁽⁶⁾

As eukaryotic, **yeasts remain unaffected** and can be taken alongside antibiotic treatments without compromising their efficacy.



S. cerevisiae var. *boulardii* has been shown to help relieve antibiotic-associated diarrhea and restore the balance of gut microbiota.⁽⁷⁾

Yeast and Common Myths

? MYTH

"Yeast can cause infections"

✓ REALITY

- Probiotic strains like *S. boulardii* are non-pathogenic, safe, and self-limiting.
- *Candida albicans* is involved in protective immune responses and is generally not harmful, unless it overgrows and becomes an infection when the balance of the gut microbiota is disrupted ⁽⁸⁾

Our proven science-backed solutions to support digestive health. Dual Yeasts, Dual Benefits.



The Most Researched and Recognized Probiotic Yeast for Digestive and Immune health ⁽⁹⁻¹¹⁾

Lynside® *S. boulardii* is an exclusive and patented probiotic yeast, registered as **S. cerevisiae CNCM I-3799** that has demonstrated clinical proven efficacy for supporting gut health.

ACUTE DIARRHEA
May alleviate **acute diarrhea** in children

TRAVELERS DIARRHEA
Helps alleviate **occasional diarrhea** while traveling

ANTIBIOTIC ASSOCIATED DIARRHEA
Helps to avoid **Antibiotic-Associated Diarrhea (AAD)**

IMMUNE SYSTEM
May support **immune health**



The Unique Science-Based Yeast Strain for IBS Symptoms Management ⁽¹²⁻¹⁴⁾

ibSium® is an exclusive and patented probiotic yeast, registered as **S. cerevisiae CNCM I-3856**, that has demonstrated clinically proven efficacy for improving digestive comfort and bowel habits.

A **ABDOMINAL PAIN ALLEVIATION**
63% of volunteers experienced a significant reduction in abdominal pain ⁽⁵⁾

B **BLOATING RELIEF**
14.6% reduction in bloating severity with ibSium® compared to placebo.⁽⁶⁾

C D **CONSTIPATION, DIARRHEA REDUCTION**
Normalization of stool consistency observed within **4 weeks** ⁽⁷⁾

E **ENHANCED QUALITY OF LIFE**
Lower food avoidance, better body image, and less interference with daily activities

Meet the future of gut health: Lynside® *S. boulardii* and ibSium®. Two unique, science-backed probiotic strains designed to relieve digestive discomfort, support IBS symptoms, and raise the standard of human health.



Connect with us to explore more!

References:

- Shkoporov AN, Hill C. Bacteriophages of the human gut: the "known unknown" of the microbiome. Cell Host Microbe. 2019; 25(2):195-209. doi:10.1016/j.chom.2019.01.017.
- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10. PMID: 24912386.
- Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019; 16(6):331-345. doi: 10.1038/s41575-019-0121-2.
- Blanquet-Diot S, Denis S, Chalancon S, Chaira F, Cardot JM, Alric M. Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans. Pharm Res. 2012 Jun;29(6):1444-53. doi: 10.1007/s11095-011-0620-5. Epub 2011 Nov 9. PMID: 22068280
- Decherf A, Dehay E, Boyer M, Clément-Ziza M, Rodriguez B, & Legrain-Raspaud, S. (2020). Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration. Nutrients, 12(8), 2211.
- Dahiya, Divakar, and Poonam Singh Nigam. "Antibiotic-therapy-induced gut dysbiosis affecting gut microbiota—brain Axis and cognition: Restoration by intake of probiotics and synbiotics."
- Kabbani, Toufic A., et al. "Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers." Gut Microbes 8.1 (2017): 17-32.
- Richard ML, Sokol H. The gut mycobiota: Insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019; 16(6):331-345. doi: 10.1038/s41575-019-0121-2.
- McFarland, L. V. "Common Organisms and Probiotics: Saccharomyces boulardii." In The Microbiota in Gastrointestinal Pathophysiology, Academic Press, 2017, pp. 145-164.
- McFarland, Lynne V., and Shan Goh. "Are Probiotics and Prebiotics Effective in the Prevention of Travellers' Diarrhea: A Systematic Review and Meta-Analysis." Travel Medicine and Infectious Disease, vol. 27, 2019, pp. 11-19.
- Stier, Heike, and Stephan C. Bischoff. "Influence of Saccharomyces boulardii CNCM I-745 on the Gut-Associated Immune System." Clinical and Experimental Gastroenterology, 2016, pp. 269-279.
- Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease; 2015 February; 47(2):119- 124.
- Spiller RS, Pelerin F, Cayzele Decherf A, Maudet C, Housez B, Cazaubiel M, Justen P. Randomized double-blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal; 2016, vol.4, 353-362
- Ravichandran Gayathri, Thangavelu Aruna, Sivaraman Malar, Bennur Shilpa, Karukkupalayam Ramasamy Dhanasekar. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. International Journal of Colorectal Disease; 2020, 35, 139-145.